Related Experiment Video

Updated: Sep 1, 2025

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.2K

Colesevelam - a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia

Oluwayemisi Esan1, Adie Viljoen2, Anthony S Wierzbicki1

  • 1Metabolic Medicine/Chemical Pathology, Guy's & St Thomas Hospitals, London, UK.

Expert Opinion on Pharmacotherapy
|August 15, 2022
PubMed

Insights

Colesevelam HCl, a bile acid sequestrant, effectively lowers LDL cholesterol and HbA1c. It offers additional benefits when combined with other lipid-lowering therapies, showing promise as a third-line treatment option.

Area of Science:

  • Cardiovascular medicine
  • Endocrinology
  • Pharmacology

Background:

  • Low-density lipoprotein cholesterol (LDL-C) is a key risk factor for cardiovascular disease (CVD).
  • Statins are primary treatments, but combination therapy is often needed for significant LDL-C reduction.
  • Colesevelam HCl is a bile acid sequestrant (BAS) with established lipid-lowering and glycemic control effects.

Purpose of the Study:

  • To evaluate the efficacy of Colesevelam HCl as a monotherapy and in combination for lipid-lowering.
  • To assess the additional benefits of Colesevelam HCl on C-reactive protein and glycemic control (HbA1c).
  • To position Colesevelam HCl within the treatment algorithm for hypercholesterolemia.

Main Methods:

  • Review of clinical studies on Colesevelam HCl efficacy and safety.
  • Analysis of LDL-C reduction percentages in monotherapy and combination therapy.
  • Evaluation of effects on C-reactive protein and HbA1c levels.

Main Results:

  • Colesevelam HCl monotherapy reduces LDL-C by 16-22%.
  • Combination therapy with Colesevelam HCl adds a further 12-14% LDL-C reduction.
  • Colesevelam HCl also reduces C-reactive protein and HbA1c, with fewer adverse effects than other BAS.

Conclusions:

  • Colesevelam HCl is an effective BAS for lowering LDL-C and improving glycemic control.
  • Its favorable side effect profile and additional benefits make it a valuable third-line agent for hypercholesterolemia.
  • Colesevelam HCl offers potential advantages in managing patients with both dyslipidemia and diabetes.
Abstract

Keywords:
Colesevelam HClbile acid sequestrantcardiovascularcholesteroldiabetes

More Related Videos

Cholesterol Efflux Assay07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.0K
Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

324

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
847
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
304
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
247
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
241
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
657
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
236